Aspect Partners
BMRN icon

Aspect Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aspect Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.66K Buy
61
+2
+3% +$126 ﹤0.01% 455
2026
Q2 		$3.38K Buy
59
+16
+37% +$876 ﹤0.01% 469
2026
Q1 		$2.43K Buy
+43
New +$2.51K ﹤0.01% 462

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Covea Finance
Covea Finance Paris, France $3.07B AUM 27.46% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Apollon Wealth Management
Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return
Secure Asset Management
Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return

Aspect Partners's BMRN Position: Q3 2026 in Review

Aspect Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 3.4% in Q3 2026, buying an estimated $126 and bringing the position to 61 shares worth $3.66K. The position accounts for ﹤0.01% of the portfolio, ranked #455.

Aspect Partners first reported a position in BMRN in Q1 2026 and has held it in 3 quarters since. 97 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Aspect Partners held 61 shares of BioMarin Pharmaceuticals worth $3.66K as of Q3 2026.
  • Aspect Partners bought 2 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $126.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #455 holding.
  • Aspect Partners first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 97 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.